ProfileGDS5678 / 1456286_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 69% 68% 68% 69% 69% 68% 69% 68% 69% 69% 69% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2385669
GSM967853U87-EV human glioblastoma xenograft - Control 24.2378969
GSM967854U87-EV human glioblastoma xenograft - Control 34.204168
GSM967855U87-EV human glioblastoma xenograft - Control 44.2173268
GSM967856U87-EV human glioblastoma xenograft - Control 54.2227869
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2468469
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2343268
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2272969
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2178168
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2345769
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2258569
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2294369
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2364869
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2300269